BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Meridian Bioscience, Inc. (VIVO) Expands Presence In Veterinary Market And Announces Agreement With Synbiotics (SBIO)


10/19/2005 5:13:02 PM

CINCINNATI--(BUSINESS WIRE)--March 16, 2005--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that its wholly owned subsidiary, Viral Antigens, Inc. (VAI), has entered into a Distribution Agreement with Synbiotics Corporation for the distribution of VAI's veterinary products through Synbiotics' global sales, marketing, and distribution channels. Synbiotics develops, manufactures, and markets veterinary diagnostic products for the animal health market and is seeking to broaden its product portfolio. Synbiotics will immediately begin marketing VAI's line of Pseudorabies Virus Antibody (PRV) test kits. VAI will continue to supply PRV test kits directly to Japan. Pseudorabies Virus (PRV) is a contagious swine disease that causes reproductive problems, including abortion, stillbirths and death losses in breeding and finishing hogs. PRV has been one of the most costly of all swine diseases to the nation's pork producers. At its peak in the 1990's, the cost to pork producers alone was estimated to be $30 million annually represented in vaccination, testing, and animal loss costs. Over the past decade, a national control and eradication program for PRV was implemented to eliminate the presence of PRV in the swine population. Today, vaccination, testing, and good disease management practices are utilized to control the impact of PRV. PRV testing has been a significant factor in the eradication of Pseudorabies in more than 20,000 farms in the U.S. Continued surveillance testing in the U.S. and efforts to eradicate PRV outside the U.S. continue to be important initiatives in controlling PRV disease.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES